Bankrupt DNA testing company 23andMe Holding (OTC:MEHCQ) is set to hold a second auction to sell its assets, including ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares experienced a significant 19% drop on Friday, May 30, following the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company ...

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 43 unusual trades. Delving into the details, we found 16% of traders were bullish, while 53% showed bearish ...

Regeneron will make an upfront payment to Hansoh ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

You may also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw its stock touch a 52-week low of $518.68 as the biotech firm contends with ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...